NCT01194882 - Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes | Biotech Hunter

Enrollment

479

Participants

Timeline

Start Date

November 16, 2010

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

HUMAN INSULIN (BIOSYNTHETIC)

Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml

DRUG

Insuplant

"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"

Trial Locations (17)

3000

Investigational Site Number 056-001, Leuven

13385

Investigational Site Number 250-007, Marseille

21000

Investigational Site Number 250-008, Dijon

31059

Investigational Site Number 250-006, Toulouse

33604

Investigational Site Number 250-010, Pessac

34295

Investigational Site Number 250-001, Montpellier

42277

Investigational Site Number 250-011, Saint-Priest-en-Jarez

54200

Investigational Site Number 250-003, Dommartin-lès-Toul

59037

Investigational Site Number 250-009, Lille

67091

Investigational Site Number 250-002, Strasbourg

72037

Investigational Site Number 250-012, Le Mans

75014

Investigational Site Number 250-005, Paris

91100

Investigational Site Number 250-004, Corbeil-Essonnes

6043CV

Investigational Site Number 528002, Roermond

2512VA

Investigational Site Number 528003, The Hague

8025AB

Investigational Site Number 528001, Zwolle

Unknown

Investigational Site Number 752-001, Stockholm